KindlyMD, Inc. (NASDAQ:NAKA) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Brokerage consensus is “Hold” for KindlyMD, based on five analysts: three buys, one hold and one sell. The average 12-month price target is $19.33.
• KindlyMD reported a quarterly loss of $6.65 per share on $35.87 million in revenue, alongside a negative 1,067.93% net margin and analysts’ projected full-year loss of $12.87 per share.
• CEO David F. Bailey purchased 4,852 shares, while insiders bought 41,904 shares worth $235,231 over the past 90 days; insiders collectively own 24.49% of the company.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) has earned an average rating of "Hold" from the five brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.3333.

Several research analysts have commented on NAKA shares. B. Riley Financial boosted their price target on shares of KindlyMD from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Thursday. TD Cowen raised their price objective on shares of KindlyMD from $1.00 to $17.00 and gave the company a "buy" rating in a report on Monday, July 27th. Wall Street Zen raised shares of KindlyMD to a "sell" rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of KindlyMD in a research note on Friday, August 7th.

KindlyMD Price Performance

NAKA stock opened at $8.13 on Monday. The business's 50-day moving average is $5.21 and its two-hundred day moving average is $6.90. The firm has a market capitalization of $145.53 million, a P/E ratio of -0.23 and a beta of 15.99. KindlyMD has a 1 year low of $3.33 and a 1 year high of $343.20.

KindlyMD (NASDAQ:NAKA - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. The firm had revenue of $35.87 million for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. On average, analysts expect that KindlyMD will post -12.87 EPS for the current year.

Insider Transactions at KindlyMD

In other KindlyMD news, CEO David F. Bailey acquired 4,852 shares of the company's stock in a transaction dated Thursday, August 20th. The shares were acquired at an average price of $6.27 per share, for a total transaction of $30,422.04. Following the acquisition, the chief executive officer owned 3,185,246 shares in the company, valued at $19,971,492.42. The trade was a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders bought 41,904 shares of company stock worth $235,231. 24.49% of the stock is owned by insiders.

Hedge Funds Weigh In On KindlyMD

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. J. Derek Lewis & Associates Inc. purchased a new position in KindlyMD in the fourth quarter valued at approximately $167,000. Virtu Financial LLC acquired a new stake in KindlyMD during the 4th quarter worth $151,000. Invesco Ltd. purchased a new stake in shares of KindlyMD in the fourth quarter valued at about $211,000. NewEdge Advisors LLC purchased a new stake in KindlyMD in the 4th quarter valued at approximately $316,000. Finally, Saba Capital Management L.P. purchased a new stake in KindlyMD in the 4th quarter valued at approximately $1,399,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.